FOLFIRI

FOLFIRI is used for colorectal cancer and gastric cancer.^[2] FOLFIRI is effective in the treatment of metastatic colorectal cancer, but it has not been shown to be effective in the adjuvant therapy of colon and rectal cancer.

The regimen consists of:

• irinotecan (180 mg/m² IV over 90 minutes) concurrently with folinic acid (400 mg/m² [or 2 x 250 mg/m²] IV over 120 minutes)
• followed by fluorouracil (400–500 mg/m² IV bolus) then fluorouracil (2400–3000 mg/m² intravenous infusion over 46 hours).

This cycle is typically repeated every two weeks. The dosages shown above may vary from cycle to cycle.

FOLFIRI is often^{[citation needed]} combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate.^[3]

In the short term, irinotecan causes diarrhea, which may be acute or delayed in onset. Long term use^{[citation needed]} of irinotecan may lead to neutropenia.^[4]

• Dose-dense chemotherapy
• FOLFIRINOX
• FOLFOX
• FOLFOXIRI
• IFL